ArticleOncology letters2019
Serum miR-22 may be a biomarker for papillary thyroid cancer.
Article in Oncology letters, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 1 synthesis or guideline pooled it, 13 citations in OpenAlex.
- Circulating microRNAs and Clinicopathological Findings of Papillary Thyroid Cancer: A Systematic Review.In vivo (Athens, Greece)Pooled it
- The role of miR-139-5p in radioiodine-resistant thyroid cancer.Journal of endocrinological investigation · 2023Article
- Study on the Potential Mechanism of miR-22-5p in Non-Small-Cell Lung Cancer.Disease markers · 2022Article
- MiR-181a promotes cell proliferation and migration through targeting KLF15 in papillary thyroid cancer.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2022Article
- miR-22 promotes stem cell traits via activating Wnt/β-catenin signaling in cutaneous squamous cell carcinoma.Oncogene · 2021Article
- miR-22 suppresses cell viability and EMT of ovarian cancer cells via NLRP3 and inhibits PI3K/AKT signaling pathway.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2021Article
- MicroRNAs in Papillary Thyroid Cancer: What Is New in Diagnosis and Treatment.Frontiers in oncology · 2021Review
- Circulating extracellular vesicle-encapsulated microRNA as screening biomarkers for intraductal papillary mucinous neoplasm.Oncology letters · 2020Article
- Review
- Serum miR-22 is a novel prognostic marker for acute myeloid leukemia.Journal of clinical laboratory analysis · 2020Article
- Increased levels of miR-372 correlate with disease progression in patients with hyperlipidemic acute pancreatitis.Experimental and therapeutic medicine · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The present study aimed to examine whether serum microRNA (miR)-22 may be considered a potential biomarker to differentiate patients with papillary thyroid cancer (PTC) from healthy controls. Reverse transcription-quantitative polymerase chain reaction demonstrated that serum miR-22 expression was significantly enhanced in patients with PTC compared with in patients with benign thyroid nodules (BTN) and healthy controls. The expression levels of miR-22 were also increased in the thyroid tissue of patients with PTC compared with in patients with BTN. In addition, increased miR-22 in the serum of patients with PTC was positively associated with metastasis. Furthermore, miR-22 serum levels were increased in patients with PTC and the B-Raf proto-oncogene, serine/threonine kinase V600E mutation. Meanwhile, compared with patients with PTC and ≤1 ng/ml thyroglobulin (Tg)-fine needle aspiration biopsy (FNAB), serum miR-22 was significantly enhanced in patients with PTC and 1-10 ng/ml Tg-FNAB and >10 ng/ml Tg-FNAB. A receiver operating characteristic analysis demonstrated that serum miR-22 distinguished patients with PTC from patients with BTN and healthy controls. In conclusion, to the best of our knowledge, the present study was the first to demonstrate that upregulation of serum miR-22 may be used as a potential biomarker to distinguish patients with PTC from healthy controls.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.